Analysis of the clinical value of early use of edaravone for treating acute cerebral hemorrhage

Objective To investigate the clinical value of early use of edaravone for treating acute cerebral hemorrhage.Methods 80cases of acute cerebral hemorrhage were randomly divided into the observation group and the control group with 40cases in each group.The control group were given conventional symptomatic treatment,based on which the observation group were treated with edaravone 2times a day with 30mg each time for 14consecutive days. Then,the hematoma volume,the edema area around the hematoma and the National Institute of Health Stroke Scale(NIHSS)scores of both groups before and after treatment were observed.Results There was no statistical significance in the comparison of the hematoma volume and the edema area around the hematoma of two groups before treatment(P 0.05).After treatment,the edema area around the hematoma of the control group was significantly smaller than that before treatment(P 0.01),and the hematoma volume and edema area around the hematoma of the observation group were significantly smaller than those before treatment(P0.01).Besides,the hematoma volume and edema area around the hematoma of the observation group were significantly smaller than those of the control group after treament(P 0.01).There was no statistical significance in the comparison of NIHSS scores of the two groups before treatment(P 0.05).After treatment,the NIHSS scores of both groups were all lower than those before treatment(P 0.01)and that of the observation group were significantly lower than that of the control group(P 0.01).Conclusion Early use of edaravone can resist oxygen(hydroxy1)free radical reactions in patients with acute cerebral hemorrhage,significantly reduce the severity of cerebral edema,and improve prognosis of patients.